Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
|
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [31] Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer
    Wang, Shu-Ping
    Li, Yu
    Huang, Shi-Hui
    Wu, Shi-Qi
    Gao, Ling-Li
    Sun, Qin
    Lin, Qian-Wen
    Huang, Lei
    Meng, Liu-Qiong
    Zou, Yi
    Zhu, Qi-Hua
    Xu, Yun-Gen
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 17413 - 17435
  • [32] Genome-wide redistribution of BRD4 binding sites in transformation resistant cells
    Si, Han
    Scaffidi, Paola
    Merchant, Anand
    Cam, Maggie
    Stahlberg, Eric
    Misteli, Tom
    Fernandez, Patricia
    GENOMICS DATA, 2015, 3 : 33 - 35
  • [33] Discovery of novel small molecules that recruit DCAF11 for selective degradation of BRD4
    Parker, G.
    Toth, J.
    Leriche, G.
    Fish, S.
    Jamborcic, A.
    Blanco, G.
    Daniele, E.
    Steadman, K.
    Li, X.
    Yang, L.
    Chien, S.
    Dearie, A.
    Chng, K.
    Green, E.
    Hocker, M.
    Zhang, Y.
    Thompson, P.
    Bailey, S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S81 - S81
  • [34] Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking
    Zhao, Hongtao
    Gartenmann, Lisa
    Dong, Jing
    Spiliotopoulos, Dimitrios
    Caflisch, Amedeo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (11) : 2493 - 2496
  • [35] Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma
    Yin, Chunjia
    Jia, Shuting
    Yang, Xiaojuan
    Wu, Liqiang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 271
  • [36] Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
    Parker, Gregory S.
    Toth, Julia I.
    Fish, Sarah
    Blanco, Gabrielle
    Kampert, Taylor
    Li, Xiaoming
    Yang, Linette
    Stumpf, Craig R.
    Steadman, Kenneth
    Jamborcic, Aleksandar
    Chien, Stephen
    Daniele, Elizabeth
    Dearie, Alejandro
    Leriche, Geoffray
    Bailey, Simon
    Thompson, Peggy A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1446 - 1458
  • [37] An interplay between BRD4 and G9a regulates skeletal myogenesis
    Yang, Naidi
    Das, Dipanwita
    Shankar, Shilpa Rani
    Goy, Pierre-Alexis
    Guccione, Ernesto
    Taneja, Reshma
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [38] Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning
    Wang, Jian
    Yang, Wanchun
    Zhao, Lu
    Wei, Benzheng
    Chen, Jianzhong
    MOLECULES, 2024, 29 (08):
  • [39] Ligand- and structure-based virtual screening to discover dual EGFR and BRD4 inhibitors
    Allen, Bryce
    Mehta, Saurabh
    Ayad, Nagi
    Schuerer, Stephan
    CANCER RESEARCH, 2015, 75
  • [40] Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches
    Luo, D.
    Tong, J. B.
    Xiao, X. C.
    Bian, S.
    Zhang, X.
    Wang, J.
    Xu, H. Y.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (12) : 985 - 1011